PLATFORMS
CRITERIA	Visx	Alcon	Zyoptix (Bausch & Lomb)
Range of Approval	-6.00 Myopia -3.00 Astigmatism -6.50 Combined	-7.00 Myopia -0.50 Astigmatism	-7.00 Myopia -3.00 Astigmatism -7.50* Combined * The widest range
Cases Performed with Wavefront-Guided (as of 8/03)	< 10,000	< 10,000	>100,000
Efficacy - Results at 6 months	20/12.5 - 74% 20/16 - 23% 20/20 - 93% ALL* (260/357**) - 95% Myopia only*** * ALL=includes myopia and astigmatism ** Only 80% of patients that started the trial were available for evaluation *** Not including 12 patients that were excluded because need of retreatment	20/12.5 - Not reported 20/16 - Not reported 20/20 - 80% Myopia only (111/139) Total 426 20/25 - 91.4% (127/139)	20/12.5 - 70.3% ALL - 74.4% Myopia only 20/16 - 30% ALL 20/20 - 91.5% ALL - 94% Myopia (340/340) 20/25 - 95.3% ALL
Increase of Best Corrected Visual Acuity (more than 1 line on vision chart)	10.4%	38%	80%
Nighttime driving difficulty compared with before surgery	Not reported	19%	40.3%
Best Corrected Visual Acuity less than 20/25 after surgery	0% (0/357)	0.2% (1/451)	0% (0/340)
Retreatment	3.4% (12/357)	None	None
Uncorrected Visual Acuity after surgery compared with Best Corrected Visual Acuity before surgery	70%	52.6%	78%
Contrast sensitivity - ability to differentiate quicker objects at a distance > 2 levels improvement	Not tested	> 15.2% Mesopic (semi-dark conditions) > 2.2% Photopic (better or light conditions)	> 22.7% Mesopic (semi-dark conditions) > 24% Photopic (better or light conditions)
Higher Order Aberations	The average HOA did not decrease	x	37.5% reduction from baseline

---

---